Logo Image
Opinion|Videos|May 22, 2024

FDA Approves Sotatercept for Pulmonary Arterial Hypertension

Marius Hoeper, MD, offers expert perspectives on the recently FDA-approved sotatercept, focusing on its mechanism of action, potential cost implications, and potential advantages and disadvantages it could offer compared with existing foundational therapies.

Episodes in this series

Video content above is prompted by the following question(s):

  • What is the mechanism of action for the recent FDA-approved drug sotatercept and how does it differ from existing pulmonary arterial hypertension (PAH) therapies?
  • Given that sotatercept is currently approved as an add-on therapy, what potential cost implications should payers and health systems consider?
  • Is sotatercept being studied as a foundational therapy for PAH? If so, what potential advantages or disadvantages could it offer compared to existing foundational therapies?

Related Content